Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance

Helen R. Stagg, Graham H. Bothamley, Jennifer A. Davidson, Heinke Kunst, Maeve K. Lalor, Marc C. Lipman, Miranda G. Loutet, Stefan Lozewicz, Tehreem Mohiyuddin, Aula Abbara, Eliza Alexander, Helen Booth, Dean D. Creer, Ross J. Harris, Onn Min Kon, Michael R. Loebinger, Timothy D. McHugh, Heather J. Milburn, Paramita Palchaudhuri, Patrick P.J. Phillips, Erik Schmok, Lucy Taylor, Ibrahim Abubakar

Source: Eur Respir J, 54 (4) 1900982; 10.1183/13993003.00982-2019
Journal Issue: October
Disease area: Respiratory infections

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Helen R. Stagg, Graham H. Bothamley, Jennifer A. Davidson, Heinke Kunst, Maeve K. Lalor, Marc C. Lipman, Miranda G. Loutet, Stefan Lozewicz, Tehreem Mohiyuddin, Aula Abbara, Eliza Alexander, Helen Booth, Dean D. Creer, Ross J. Harris, Onn Min Kon, Michael R. Loebinger, Timothy D. McHugh, Heather J. Milburn, Paramita Palchaudhuri, Patrick P.J. Phillips, Erik Schmok, Lucy Taylor, Ibrahim Abubakar. Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance. Eur Respir J, 54 (4) 1900982; 10.1183/13993003.00982-2019

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: